Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis

Kim, Youngran; Krause, Trudy Millard; Blum, Philip; Freeman, Léorah

doi:10.1016/j.msard.2019.02.006

Cited by 26 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of 15,902 commercially insured patients with MS in the USA, mean annual healthcare charges (reported in 2011 US dollars) were estimated to be $27,000, and increased with worsening disability (mild-moderate disability, $30,000; moderate disability, $50,000; severe disability, more than $100,000) [ 17 ]. In a more recent evaluation of patients with MS, the annual total healthcare expenditure (reported in 2015 US dollars) was estimated to be $62,500 per patient [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice

et al. 2021

View full text Add to dashboard Cite

Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition characterized by unpredictable relapses that affect the optic nerves and spinal cord, which can lead to blindness, paralysis, and increased mortality rates. Evidence on the clinical and economic burden of NMOSD in the USA is currently lacking. Methods: A retrospective, observational cohort study was conducted using data from the IQVIA

show abstract

Section: Discussionmentioning

confidence: 99%

Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The findings of a study indicated that the cost of annual health care per MS patient increased from $ 45,471 in 2011 to $ 62,500 in 2015, representing an average annual growth of 8.3%. In addition, the annual cost of purchasing medication for each MS patient increased from $ 26,772 to $ 43,606, with an average annual growth rate of 13.0% [ 23 ]. A study conducted in Spain also found that the total cost of MS was € 1395 million per year, with an average annual cost of € 30,050 per patient.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Rezaee

Morowvat

Poursadeghfard

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Introduction Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths of the nerve cells in the brain and spinal cord, which are responsible for communication, are destroyed and cause physical signs and symptoms. According to studies, anti-CD20 monoclonal antibodies have significant results in the treatment of this disease. Thus, the aim of the present study was to determine the cost-effectiveness of rituximab against natalizumab in the patients with RRMS in southern Iran in 2020. Methods This is an economic evaluation including cost-effectiveness analysis in which the Markov model with a lifetime horizon was used. The study sample consisted of 120 patients randomly selected from among those referred to the MS Association and the Special Diseases Unit of Shiraz University of Medical Sciences. In this study, the costs were collected from a societal perspective, and the outcomes were obtained in the form of Quality Adjusted Life Years (QALY) and the mean relapse rate. The TreeAge pro 2020 and Excel 2016 software were used for data analysis. Results The comparative study of rituximab and natalizumab showed that the patients receiving rituximab had lower costs ($ 58,307.93 vs. $ 354,174.85) and more QALYs (7.77 vs. 7.65). In addition, the incidence of relapse by rituximab was lower compared to natalizumab (1.15 vs. 2.57). The probabilistic one-way sensitivity analysis showed the robustness of the results. The scatter plots also showed that rituximab was more cost-effective for the patients in 100% of the simulations for the threshold of < $ 37,641. Discussion and conclusion According to the results of this study, rituximab had higher cost-effectiveness than natalizumab. Therefore, it could be a priority for RRMS patients compared to natalizumab because it reduced treatment costs and increased effectiveness.

show abstract

“…7,8 Studies suggest healthcare spending can exceed $68,000 per year (2020 US dollars). 7,9 The introduction and proliferation of diseasemodifying therapies (DMTs) for MS have revolutionized the prognosis for patients. Despite a growing array of DMT options for patients and neurologists, enthusiasm for these drugs has been diminished because of rising costs.…”

Section: Introductionmentioning

confidence: 99%

“…However, for individuals with MS, spending on pharmaceuticals accounts for more than two-thirds of total healthcare expenditures. 7,9,10 DMTs constitute the single greatest driver of pharmaceutical and total healthcare spending for MS. From 2009 to 2015, total healthcare costs per person nearly doubled from $23,900 to $39,600 annually between 2009 and 2015; MS DMTs spending accounted for 82% of this increase. 10 In contrast, spending on inpatient and outpatient professional services increased 11% during this period, and constituted less than 30% of total MS-related healthcare expenditures by 2015.…”

Section: Introductionmentioning

confidence: 99%

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Hartung

2021

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.

show abstract

Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis

Cited by 26 publications

References 22 publications

Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice

Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Contact Info

Product

Resources

About